Shufro Rose & Co’s Allergan plc AGN.PRA Stock Holding History

Shufro Rose & Co’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-248	Closed	-$215K	–	290
2017 Q2	$215K	Buy	+248	New	+$208K	0.02%	242
2016 Q3	–	Hold	0	–	–	–	237

Other funds holding AGN.PRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.94B AUM 9.49% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Shufro Rose & Co's AGN.PRA Position: Q3 2017 in Review

Shufro Rose & Co sold out of Allergan plc (AGN.PRA) in Q3 2017, closing a stake of 248 shares — an estimated $215K sold.

Shufro Rose & Co first reported a position in AGN.PRA in Q2 2017 and held it in 1 quarter. The position peaked at $215K in Q2 2017. 106 funds tracked by Wall St. Rank hold AGN.PRA as of Q3 2017.

Shufro Rose & Co reported no remaining Allergan plc position as of Q3 2017 after selling out during the quarter.
Shufro Rose & Co sold 248 Allergan plc shares in Q3 2017, an estimated $215K.
Shufro Rose & Co first reported a position in Allergan plc in Q2 2017 and held it in 1 quarter.
Shufro Rose & Co's Allergan plc position peaked at $215K in Q2 2017.
106 funds tracked by Wall St. Rank held Allergan plc as of Q3 2017.

Based on Shufro Rose & Co's 13F filing for Q3 2017, filed 13 Nov 2017.